PDCD1 and cancer: Furthermore, a small fraction of patients with cancer receiving PD-1-based immunotherapy succumbs to HPD.20 Hence, there is a critical need to determine the cause for the beneficial or deleterious effects of PD-1 blockade therapy in patients.